Madopar® 250 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03097211 (ClinicalTrials.gov)	July 17, 2006	27/3/2017	Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg	A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg	Parkinson Disease	Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	38	Phase 1	Portugal
2	NCT03094156 (ClinicalTrials.gov)	April 26, 2006	23/3/2017	Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics	A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mg	Parkinson Disease	Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan®	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	39	Phase 1	Portugal